Key Highlights

• Audeara has launched the process for a US OTC listing following what the company described as a record FY26.

• The company secured an exclusive deal with Shokz Health Global during April 2026.

• Audeara announced a chip-level AI licensing Partnership moving into commercial production in August.

• AUA is trading at AUD 0.027, up 17.39% during Tuesday's session.

Audeara (ASX:AUA) is trading at AUD 0.027 during Tuesday's session, up 17.39%, as the hearing-health technology company moves into a new financial year with several commercial initiatives in progress. September has brought a fresh corporate step through the launch of a US OTC listing process, following a year in which Audeara expanded partnerships, advanced licensing activity and raised additional capital. The company has described FY26 as a record year, setting the backdrop for its next phase of distribution and technology commercialisation.

US OTC Process Extends the Investor Footprint

On 14 September, Audeara announced that it had launched the process for a US OTC listing following its FY26 performance. The step is designed to provide an additional trading avenue in the United States while the company's primary listing remains on the ASX. Audeara already operates within international hearing-health markets, so the proposed OTC presence adds a capital-markets dimension to its existing commercial exposure. The process itself does not change the company's operating model, but it may broaden accessibility for US-based investors if completed.

FY26 Brings Multiple Commercial Developments

Audeara's FY26 announcements show activity across product distribution, technology licensing and Capital management. In April, the company announced an exclusive deal with Shokz Health Global. The arrangement added another commercial channel within hearing health, complementing Audeara's own personalised listening products. In August, the company announced a chip-level AI licensing partnership that had moved to commercial production. That initiative extends Audeara's technology beyond finished headphones by licensing elements of its audio and hearing-related capability for integration at the chip level.

Capital Raising Supports the Next Stage

Audeara announced in August that it had received firm commitments for an AUD 1.26mn placement. The raising followed a Trading halt and was accompanied by securities documentation later in the month. For a small technology company, access to capital remains relevant as it balances product development, inventory, commercial partnerships and expansion initiatives. The Placement provides additional funding as Audeara progresses its international strategy and works to convert partnerships into recurring commercial activity.

Company Introduction

Audeara is an Australian hearing-health technology company that develops personalised listening products for people with hearing challenges. Its headphones use a hearing-check algorithm to tailor sound to an individual's hearing profile. The company's products are designed and engineered in Australia and can be used alongside hearing aids and cochlear implants. Audeara sells through distributors, resellers and E-commerce channels, with operations extending beyond Australia. Its commercial strategy increasingly combines branded products with partnerships and technology licensing.

Sector Context

Audeara sits at the intersection of consumer electronics and hearing health. Its products compete for attention in a market where conventional audio devices, assistive listening devices and hearing technologies increasingly overlap. The company's differentiation is built around personalised audio and hearing-profile calibration rather than standard consumer headphone functionality alone. Commercial progress therefore depends not only on product sales but also on distributor relationships, healthcare channels, licensing arrangements and the ability to integrate its technology into third-party platforms. The Shokz Health and chip-level licensing announcements illustrate this broader route to market.

Risks to Consider

Audeara remains a small-cap company operating in competitive consumer electronics and hearing-health markets. Commercial partnerships may take time to translate into material revenue, while product sales can be influenced by distributor performance, inventory requirements and consumer demand. International expansion introduces additional execution, regulatory and currency considerations. The company also needs to manage cash requirements as it invests in growth. Technology licensing can broaden the Business model, but the timing and scale of future royalties or production-linked Revenue will depend on partner execution and end-market adoption.

Things to Watch Next

The next milestones include progress on the US OTC listing process, further information on the chip-level AI licensing partnership and evidence of commercial traction from distribution agreements. Investors will also be watching how the AUD 1.26mn placement supports the company's operating priorities and whether FY27 can build on the activity reported for FY26. AUA is trading at AUD 0.027, up 17.39% during Tuesday's session. The stock is also up 17.39% over one year, putting delivery against the company's expanded commercial pipeline in focus.

Summary

Audeara enters FY27 with an expanded partnership and licensing pipeline, while the US OTC process, distribution execution and conversion of technology agreements into commercial revenue remain key areas to watch.